Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55
Repare Therapeutics (NASDAQ:RPTX) Shares Gap Down to $14.55
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) shares gapped down prior to trading on Friday . The stock had previously closed at $14.55, but opened at $13.89. Repare Therapeutics shares last traded at $13.93, with a volume of 400 shares.
Repare治療公司(納斯達克代碼：RPTX-GET評級)的股價在週五交易前大幅下跌。該股此前收盤報14.55美元，開盤報13.89美元。Repare Treateutics的股票尾盤報13.93美元，成交量為400股。
Analyst Ratings Changes
分析師評級發生變化
A number of analysts have recently issued reports on the stock. Capital One Financial initiated coverage on shares of Repare Therapeutics in a report on Friday. They set an "overweight" rating and a $28.00 price target for the company. HC Wainwright dropped their price target on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $30.80.
一些分析師最近發佈了關於該股的報告。Capital One Financial在週五的一份報告中啟動了對Repare治療公司股票的覆蓋。他們為該公司設定了“增持”評級和28.00美元的目標價。11月17日星期四，HC Wainwright在一份研究報告中將Repare Treateutics的股票目標價從38.00美元下調至25.00美元，併為該公司設定了“買入”評級。一名分析師對該股的評級為持有，五名分析師對該公司的評級為買入。根據MarketBeat的數據，該公司的普遍評級為“適度買入”，平均目標價為30.80美元。
Repare Therapeutics Price Performance
修復治療藥物的價格表現
The firm's 50-day simple moving average is $15.56 and its two-hundred day simple moving average is $13.94. The company has a market capitalization of $615.55 million, a price-to-earnings ratio of -19.93 and a beta of 0.11.
該公司50日簡單移動均線切入位為15.56美元，200日簡單移動均線切入位為13.94美元。該公司市值為6.1555億美元，市盈率為-19.93倍，貝塔係數為0.11。
Insider Activity at Repare Therapeutics
Repare治療公司的內部活動
In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction that occurred on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the transaction, the director now owns 2,094,451 shares of the company's stock, valued at $33,511,216. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.60% of the company's stock.
在相關新聞中，董事戴維斯·傑裏爾在12月9日(星期五)的一筆交易中出售了250,000股該公司股票。這些股票的平均價格為16.00美元，總成交金額為4,000,000.00美元。交易完成後，董事現在持有該公司2,094,451股股票，價值33,511,216美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過這個環節。內部人士持有該公司33.60%的股份。
Hedge Funds Weigh In On Repare Therapeutics
對衝基金參與Repare Treeutics
A number of large investors have recently bought and sold shares of the stock. Deep Track Capital LP raised its stake in Repare Therapeutics by 26.9% during the first quarter. Deep Track Capital LP now owns 2,664,017 shares of the company's stock worth $37,936,000 after purchasing an additional 564,017 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Repare Therapeutics by 72.5% in the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company's stock worth $6,677,000 after acquiring an additional 197,127 shares in the last quarter. BlackRock Inc. increased its position in shares of Repare Therapeutics by 1.9% in the first quarter. BlackRock Inc. now owns 467,311 shares of the company's stock worth $6,655,000 after acquiring an additional 8,680 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new stake in shares of Repare Therapeutics in the third quarter worth $2,269,000. Finally, Renaissance Technologies LLC increased its position in shares of Repare Therapeutics by 105.3% in the second quarter. Renaissance Technologies LLC now owns 180,900 shares of the company's stock worth $2,531,000 after acquiring an additional 92,800 shares in the last quarter. Hedge funds and other institutional investors own 78.19% of the company's stock.
一些大型投資者最近買賣了該股的股票。第一季度，Deep Track Capital LP將其在Repare Treateutics的持股增加了26.9%。在此期間，Deep Track Capital LP額外購買了564,017股，目前擁有2,664,017股該公司股票，價值37,936,000美元。Affiliation Asset Advisors LLC在第一季度將其在Repare Treeutics股票的持倉增加了72.5%。Affiliation Asset Advisors LLC在上個季度增持了197,127股後，現在擁有468,905股該公司股票，價值6,677,000美元。貝萊德股份有限公司在第一季度增持了Repare治療公司的股票1.9%。貝萊德股份有限公司在上個季度增持了8,680股後，目前持有467,311股該公司股票，價值6,655,000美元。三井住友信託控股公司在第三季度收購了價值226.9萬美元的Repare治療公司的新股份。最後，復興科技有限責任公司在第二季度將其在Repare治療公司的股票持有量增加了105.3%。復興科技有限責任公司在上個季度增持了92,800股後，現在擁有180,900股該公司股票，價值2,531,000美元。對衝基金和其他機構投資者持有該公司78.19%的股份。
About Repare Therapeutics
關於Repare Treeutics
(Get Rating)
(獲取評級)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare治療公司是一家臨牀階段的精確腫瘤學公司，通過在加拿大和美國使用其合成致命性方法來發現和開發治療方法。該公司使用其SNIPRx，這是一個專有的、全基因組的和支持CRISPR的平臺，以系統地發現和開發專注於基因組不穩定性(包括DNA損傷修復)的高度針對性的癌症療法。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
- Is Your Portfolio Flexible Enough for FLEX Stock?
- How 2022's Biggest Healthcare Gainers Could Fare In 2023
- 免費獲取StockNews.com關於Repare治療的研究報告(RPTX)
- 2023年四隻被低估的醫療保健股票
- WWE股票：文斯·麥克馬洪想要重返節目
- NVIDIA正在觸底，但現在還不能買入
- 你的投資組合對Flex股票足夠靈活嗎？
- 2022年最大的醫療保健獲益者在2023年的表現如何
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Repare治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Repare Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。